Petitioner Must Show Actual Injury to Establish Standing to Appeal PTAB Final Written Decision

Jan 17, 2017

Reading Time : 2 min

Phigenix, the party seeking judicial review, bears the burden to establish standing.  To prove standing, Phigenix must establish that (1) it suffered an injury in fact, (2) the injury is fairly traceable to challenged conduct of ImmunoGen, and (3) the injury is likely to be redressed by a favorable judicial outcome. First, the Federal Circuit addressed threshold issues of the burden of production, evidence to meet that burden, and when the evidence must be produced in cases where the appellant seeks review of final agency actions and its standing is challenged. The appellant’s burden of production is the same as a plaintiff moving for summary judgment in district court. An appellant is permitted to supplement the administrative record with arguments, affidavits or other evidence to demonstrate its standing, if the appellant’s standing is not self-evident (i.e., the appellant is not “an object of the action (or forgone action) at issue.”). Sierra Club v. EPA, 292 F.3d 895, 900 (D.C. Cir. 2002) (quoting Lujan v. Defs. Of Wildlife, 504 U.S. 555, 561-62 (1992)). Finally, if there is no evidence on the record to support standing, the appellant must provide evidence establishing its standing at the earliest possible opportunity because standing involves threshold questions over the court’s authority to hear the dispute.  

The Federal Circuit held that Phigenix did not have standing to appeal the PTAB decision in federal court because it failed to establish that it suffered an injury. Phigenix asserted that although it does not face the risk of infringing the ’856 patent, it has suffered actual economic injury because the ’856 patent increases competition between Phigenix and ImmunoGen for licensing revenue. The Federal Circuit held that the documents and declarations Phigenix relied on to support its claim are insufficient to show injury in fact because they are merely a conclusory statement about a hypothetical licensing injury and do not establish that Phigenix ever licensed the ’534 patent to anyone, let alone to entities that obtained licenses to ImmunoGen’s ’856 patent. Phigenix’s remaining arguments that it suffered an injury based on the estoppel effect of the PTAB’s decision and the violation of its procedural right to seek an appeal under 35 U.S.C. § 141 (c) were also denied. Thus, Phigenix’s appeal of the PTAB’s decision was dismissed.

Phigenix, Inc. v. ImmunoGen, Inc., No. 2016-1544 (Fed. Cir. Jan. 9, 2017).   

Share This Insight

Previous Entries

IP Newsflash

October 1, 2025

In a recent final written decision, the PTAB determined that a reference patent was not prior art, despite the petitioner’s post‑filing attempt to correct its petition. While the petitioner argued that it intended to rely on the patent application’s earlier date of publication, both the corrected petition and the expert declaration continued to reference the issued patent rather than the published application.

...

Read More

IP Newsflash

September 30, 2025

The USPTO Director recently granted a petitioner’s request for rehearing of the decision discretionarily denying institution of inter partes review, ultimately vacating the original decision, and referring the petition to the board for an institution decision.

...

Read More

IP Newsflash

September 25, 2025

In considering claims to a method of reducing cardiovascular events, the Federal Circuit held that the term a “clinically proven effective” amount did not render the claims patentable over the prior art. Specifically, the Federal Circuit held that the “clinically proven effective” amount, whether limiting or not, could not be used to distinguish the prior art because the claims also specified the exact amount of the drugs to be administered in the method. The Federal Circuit also rejected patentee’s evidence of unexpected results because that evidence was tied solely to the “clinically proven effective” limitation.

...

Read More

IP Newsflash

September 24, 2025

The Federal Circuit reversed a district court’s denial of judgment as a matter of law on non-infringement, thereby setting aside a $106 million jury verdict, after holding that prosecution history estoppel barred the patentee from asserting infringement under the doctrine of equivalents.

...

Read More

IP Newsflash

September 17, 2025

A magistrate judge in the District of Delaware issued a Report and Recommendation, that found the sole asserted claim was a “single means” claim and therefore invalid for lack of enablement. In reaching that conclusion, the magistrate judge rejected the patentee’s argument that the preamble of the claim disclosed a second element that satisfied the combination requirement of Section 112, paragraph 6 because the preamble simply recited a descriptor of the very apparatus that was the subject of the means-plus-function limitation in the body of the claim. The district court judge presiding over this case has scheduled a hearing to review the magistrate’s ruling.

...

Read More

IP Newsflash

September 9, 2025

The Federal Circuit has affirmed the PTAB’s determination that a patent challenger did not show the challenged claims were unpatentable for obviousness. The Federal Circuit concluded that substantial evidence, which included expert testimony, showed there was no motivation to combine the references.

...

Read More

IP Newsflash

August 29, 2025

In a recent order addressing four IPR proceedings, the PTAB exercised its inherent authority under 37 C.F.R. § 42.5(a) to sua sponte authorize post-hearing discovery on a potentially dispositive privity issue. The order followed a Director review decision that vacated and remanded earlier IPRs involving the same parties, patent family, and privity issue. 

...

Read More

IP Newsflash

August 29, 2025

The Patent Trial and Appeal Board denied institution of an inter partes review petition in part because it determined that a patent reference was not prior art under the common ownership exception of pre-AIA 35 U.S.C. § 103(c)(1).

...

Read More

© 2025 Akin Gump Strauss Hauer & Feld LLP. All rights reserved. Attorney advertising. This document is distributed for informational use only; it does not constitute legal advice and should not be used as such. Prior results do not guarantee a similar outcome. Akin is the practicing name of Akin Gump LLP, a New York limited liability partnership authorized and regulated by the Solicitors Regulation Authority under number 267321. A list of the partners is available for inspection at Eighth Floor, Ten Bishops Square, London E1 6EG. For more information about Akin Gump LLP, Akin Gump Strauss Hauer & Feld LLP and other associated entities under which the Akin Gump network operates worldwide, please see our Legal Notices page.